Recent Updates
Recently added Catalysts

Investigational Seasonal Affective Disorder Drug

Phase 3

Seasonal Affective Disorder (SAD) | Small molecule | Psychiatry |GSK plc|Last Updated: Jun 4, 2015

Target and mechanism

ModalitySmall molecule

Also known as Investigational Seasonal Affective Disorder (SAD) Drug

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment -

FDA Designations

No designations recorded

Clinical trial landscape

Investigational Seasonal Affective Disorder Drug · 1 trial · 1 indication

Phase 3 1
NCT00046449Prevention of Seasonal Affective DisorderSeasonal Affective Disorder (SAD)
COMPLETED- Analytics
PHASE3COMPLETED
Prevention of Seasonal Affective Disorder
Seasonal Affective Disorder (SAD)Unlock trial analytics

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT

Interventions

NameTypeDescription
Investigational Seasonal Affective Disorder (SAD) DrugDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites54

Inclusion Criteria: (Patient must meet these criteria in order to be eligible for this study.) * Patient has a history of Major Depressive Disorder (MDD) with a seasonal pattern. Exclusion Criteria: (Patient cannot meet these criteria in order to be eligible for this study.) * Patient has a curre...

Countries:United StatesCanada
Unlock Eligibility Criteria